Building Indiana reports that powerhouse Eli Lilly has inked a global licensing and research collaboration with ImmuNext, Inc. to study preclinical novel targets that could lead to identification of new medicines for autoimmune diseases by regulating immune cell...
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok